Ascentage Pharma
AAPG
8 hedge funds and large institutions have $264K invested in Ascentage Pharma in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
14% more funds holding
Funds holding: 7 → 8 (+1)
0.02% less ownership
Funds ownership: 0.03% → 0.02% (-0.02%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
63% less capital invested
Capital invested by funds: $722K → $264K (-$458K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$8.96K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$4.26K |
| 3 |
BlackRock
New York
|
+$128 |
| 4 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$21 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XC
XY Capital
Central,
Hong Kong
|
-$311K |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$47.2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$12.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.32K |
AAPG Hedge Fund Activity: Q2 2026 in Review
8 of the 8,344 institutional investors tracked by Wall St. Rank reported a position in Ascentage Pharma (AAPG) for Q2 2026, worth a combined $264K — down 63% from $722K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new AAPG positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $8.96K. The largest seller was XY Capital, exiting entirely with an estimated $311K sold.
- 8 institutional investors held Ascentage Pharma (AAPG) as of Q2 2026, up from 7 in Q1 2026.
- Funds reported $264K of Ascentage Pharma stock for Q2 2026, down 63% quarter-over-quarter.
- 3 funds opened new Ascentage Pharma positions in Q2 2026 and 2 closed out, a net change of +1 holder.
- The largest Ascentage Pharma buyer in Q2 2026 was Morgan Stanley, an estimated $8.96K added.
- The largest Ascentage Pharma seller in Q2 2026 was XY Capital, an estimated $311K sold.
Based on aggregated 13F filings for Q2 2026.